Companies › Faron Pharmaceuticals
1 active drug program in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| bexmarilimab | – | Phase 2 | Higher Risk Myelodysplastic Syndromes; Acute Myeloid Leukemia; Soft Tissue Sarcoma (STS); Melanoma (Skin Cancer) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05428969 | bexmarilimab | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT07672769 | bexmarilimab | Phase 2 | Higher Risk Myelodysplastic Syndromes | Oncology | Nov 2027 |
| NCT07460986 | bexmarilimab | Phase 1 | Soft Tissue Sarcoma (STS) | Oncology | Jul 2028 |
| NCT07718243 | bexmarilimab | Phase 1 | Melanoma (Skin Cancer) | Oncology | Jan 2030 |
No annotated target.
–
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.